Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
706 (USA) · Dr. Rossi
consented 2013-05-14
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-06-03 (study day 21.0); relationship: POSSIBLE
severe
assessed
Severe SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-06-18 (study day 36.0); relationship: PROBABLE; serious criteria: hospitalization
Data queries
No data queries.